Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
The role of liquid biopsies in prostate cancer management
Lab on a Chip ( IF 6.1 ) Pub Date : 2021-07-23 , DOI: 10.1039/d1lc00485a Chi-Ju Kim 1 , Liang Dong , Sarah R Amend , Yoon-Kyoung Cho , Kenneth J Pienta
Lab on a Chip ( IF 6.1 ) Pub Date : 2021-07-23 , DOI: 10.1039/d1lc00485a Chi-Ju Kim 1 , Liang Dong , Sarah R Amend , Yoon-Kyoung Cho , Kenneth J Pienta
Affiliation
|
Liquid biopsy has emerged as a complement to invasive tissue biopsy to guide cancer diagnosis and treatment. The common liquid biopsy biomarkers are circulating tumor cells (CTCs), extracellular vesicles (EVs), and circulating tumor DNA (ctDNA). Each biomarker provides specific information based on its intrinsic characteristics. Prostate cancer is the second most common cancer in males worldwide. In men with low-grade localized prostate cancer, the disease can often be managed by active surveillance. For men who require treatment, the 5-year survival rate of localized prostate cancer is the highest among all cancer types, but the metastatic disease remains incurable. Metastatic prostate cancer invariably progresses to involve multiple bone sites and develops into a castration-resistant disease that leads to cancer death. The need to appropriately diagnose and guide the serial treatment of men with prostate cancer has led to the implementation of many studies to apply liquid biopsies to prostate cancer management. This review describes recent advancements in isolation and detection technology and the strength and weaknesses of the three circulating biomarkers. The clinical studies based on liquid biopsy results are summarized to depict the future perspective in the role of liquid biopsy on prostate cancer management.
中文翻译：
液体活检在前列腺癌治疗中的作用
液体活检已成为侵入性组织活检的补充，以指导癌症诊断和治疗。常见的液体活检生物标志物是循环肿瘤细胞 (CTC)、细胞外囊泡 (EV) 和循环肿瘤 DNA (ctDNA)。每个生物标志物根据其内在特征提供特定信息。前列腺癌是全球男性中第二常见的癌症。在患有低级别局限性前列腺癌的男性中，这种疾病通常可以通过主动监测来控制。对于需要治疗的男性，局限性前列腺癌的 5 年生存率是所有癌症类型中最高的，但转移性疾病仍然无法治愈。转移性前列腺癌总是会进展到涉及多个骨骼部位，并发展成一种导致癌症死亡的去势抵抗疾病。需要适当地诊断和指导前列腺癌男性的连续治疗，这导致了许多研究的实施，以将液体活检应用于前列腺癌的治疗。本综述描述了分离和检测技术的最新进展以及三种循环生物标志物的优缺点。总结了基于液体活检结果的临床研究，以描述液体活检在前列腺癌治疗中的作用的未来前景。
更新日期：2021-08-04
中文翻译：
液体活检在前列腺癌治疗中的作用
液体活检已成为侵入性组织活检的补充，以指导癌症诊断和治疗。常见的液体活检生物标志物是循环肿瘤细胞 (CTC)、细胞外囊泡 (EV) 和循环肿瘤 DNA (ctDNA)。每个生物标志物根据其内在特征提供特定信息。前列腺癌是全球男性中第二常见的癌症。在患有低级别局限性前列腺癌的男性中，这种疾病通常可以通过主动监测来控制。对于需要治疗的男性，局限性前列腺癌的 5 年生存率是所有癌症类型中最高的，但转移性疾病仍然无法治愈。转移性前列腺癌总是会进展到涉及多个骨骼部位，并发展成一种导致癌症死亡的去势抵抗疾病。需要适当地诊断和指导前列腺癌男性的连续治疗，这导致了许多研究的实施，以将液体活检应用于前列腺癌的治疗。本综述描述了分离和检测技术的最新进展以及三种循环生物标志物的优缺点。总结了基于液体活检结果的临床研究，以描述液体活检在前列腺癌治疗中的作用的未来前景。
京公网安备 11010802027423号